Orexo Management
Management criteria checks 3/4
Orexo's CEO is Nikolaj Sorensen, appointed in Feb 2013, has a tenure of 13.5 years. total yearly compensation is SEK6.99M, comprised of 57% salary and 43% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth SEK3.18M. The average tenure of the management team and the board of directors is 4 years and 3.6 years respectively.
Key information
Nikolaj Sorensen
Chief executive officer
SEK 7.0m
Total compensation
| CEO salary percentage | 56.96% |
| CEO tenure | 13.5yrs |
| CEO ownership | 0.6% |
| Management average tenure | 4yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Narrative Update • Jun 13
ORX: Overdose Reversal Pipeline Progress Will Support Future Upside
Orexo's SEK price target remains unchanged at SEK 29. Analysts have kept the fair value steady and point to relatively stable assumptions for the discount rate, revenue growth, profit margin and future P/E in their updated work.Narrative Update • May 30
ORX: Overdose Treatment Progress And Higher Margins Will Support Future Upside
Analysts now see Orexo's fair value at SEK29.0, down from SEK38. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E, alongside a modest increase in the discount rate.Narrative Update • Apr 25
ORX: Higher Profit Margins And Lower P/E Assumptions Will Support Future Upside
Analysts have adjusted their view on Orexo with a modest shift in price expectations in SEK terms, citing slightly higher projected profit margins at 19.52% and a lower assumed future P/E of 124.01x as key factors behind the new price target. Valuation Changes Fair Value: SEK 38.0 remains unchanged compared with the previous SEK 38.Narrative Update • Apr 09
ORX: Steady Margins And Elevated P/E Multiple Will Support Future Upside Potential
Analysts have kept their SEK price target for Orexo broadly steady, with only a marginal adjustment that reflects slightly revised views on long term profit margins and the future P/E multiple, while leaving fair value, discount rate, and revenue growth assumptions effectively unchanged. Valuation Changes Fair Value: SEK 38.0 per share, effectively unchanged from the previous SEK 38.Narrative Update • Mar 26
ORX: Stable Margins And High P/E Multiple Will Support Upside Potential
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK38.0, reflecting only minor tweaks to long term margin and P/E assumptions rather than any shift in the core thesis. Valuation Changes Fair Value: SEK38.0 remains essentially unchanged compared with the prior SEK38 estimate.Narrative Update • Mar 12
ORX: Future P/E Support Will Rely On Stable Margins
Analysts have kept their SEK fair value estimate for Orexo broadly unchanged at SEK 38.0. This reflects only minor tweaks to underlying assumptions, such as slightly higher modeled revenue growth and a marginally lower future P/E multiple. Valuation Changes Fair Value: SEK 38.0 per share, unchanged from the prior SEK 38 estimate.Narrative Update • Feb 25
ORX: Future P E Multiple Will Rely On Sustained Margin Support
Analysts have raised their price target for Orexo to SEK 38, citing an assumed revenue growth rate of 35% and a projected future P/E of about 129, while forecast profit margins are expected to ease to around 19%. Valuation Changes Fair Value: SEK 38 is unchanged, with the updated estimate remaining at SEK 38.0. Discount Rate: 5.224% is unchanged between the previous and updated assumptions.Narrative Update • Feb 06
ORX: Higher Required Return Will Still Support Very Large Future P E Multiple
Narrative Update Analysts have trimmed their price target on Orexo to US$38.00, reflecting slightly higher discount rate assumptions and a modestly lower profit margin outlook. They are still applying a very large forward P/E multiple that keeps the fair value estimate unchanged at US$38.00.Narrative Update • Jan 22
ORX: Stable Assumptions And Elevated P/E Will Support Long Term Upside
Analysts have kept their fair value target for Orexo unchanged at $38.00, citing largely stable assumptions around the discount rate, revenue expectations, profit margin, and a very high forward P/E estimate. Valuation Changes Fair Value: Kept unchanged at SEK 38.00 per share, reflecting stable core assumptions.Narrative Update • Jan 07
ORX: Revised Earnings Assumptions Will Shape Balanced Long Term Prospects
Analysts have raised their price target on Orexo from SEK 31 to SEK 38, citing a substantial revision to future P/E assumptions and significantly lower revenue growth expectations, while keeping profit margin and discount rate inputs broadly unchanged. Valuation Changes Fair Value Target: raised from SEK 31 to SEK 38, reflecting a higher indicated equity value per share.Narrative Update • Dec 14
ORX: New Science Park Facilities Will Support Stronger Long Term Prospects
Analysts have modestly raised their price target on Orexo to $31.00, highlighting a slightly richer future earnings multiple that is expected to offset a small anticipated erosion in long term profit margins. What's in the News Relocating to new, modern premises in Uppsala Science Park to support the next phase of the company’s development and growth (Key Developments) New facilities include laboratories, cleanrooms, and flexible office spaces designed to strengthen research and development capabilities (Key Developments) Site designed with a clear sustainability profile, featuring energy and cost efficient solutions to reduce environmental impact (Key Developments) Move aims to foster greater collaboration and innovation with partners, academia, healthcare providers, and patients (Key Developments) Valuation Changes Fair Value: Unchanged at SEK 31.0 per share, indicating no revision to the central valuation estimate.Narrative Update • Nov 28
ORX: New Facility Move And R&D Will Drive Future Performance
Analysts have updated their price target for Orexo to $31.00. They are maintaining their previous estimate, as underlying assumptions around revenue growth and discount rates remain largely unchanged.Narrative Update • Nov 13
ORX: Future Profit Margin Gains And R&D Move To Support Outlook
Narrative Update on Orexo Analysts have maintained their fair value estimate for Orexo at $31.00, citing stable expectations for revenue growth and recent improvements in profit margin projections as key factors supporting their unchanged price target. What's in the News Orexo AB is relocating to modern premises in Uppsala Science Park to strengthen research and development, enhance collaboration, and promote sustainability within its operations (Key Developments).Analysis Article • Nov 02
Why Investors Shouldn't Be Surprised By Orexo AB (publ)'s (STO:ORX) 28% Share Price Plunge
Orexo AB (publ) ( STO:ORX ) shares have retraced a considerable 28% in the last month, reversing a fair amount of their...Narrative Update • Oct 30
ORX: Relocation And In-Vivo Results Will Support Measured Opportunity Ahead
Analysts have raised their price target for Orexo to $31.00 per share. This update reflects improving revenue growth forecasts and a slightly higher projected profit margin.Narrative Update • Oct 16
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Analysts have raised their price target for Orexo from $21.50 to $31.00. This decision is based on updated valuation methodologies, even as growth and margin expectations have been slightly adjusted.Analysis Article • Sep 16
There's No Escaping Orexo AB (publ)'s (STO:ORX) Muted Revenues Despite A 29% Share Price Rise
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 29% share price jump in the last...Analysis Article • Jun 10
Orexo AB (publ) (STO:ORX) Shares Fly 32% But Investors Aren't Buying For Growth
Orexo AB (publ) ( STO:ORX ) shareholders have had their patience rewarded with a 32% share price jump in the last...Analysis Article • May 09
Orexo AB (publ) (STO:ORX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Orexo AB (publ) ( STO:ORX ) investors will be delighted, with the company turning in some strong numbers with its...Analysis Article • May 02
Shareholders May Not Be So Generous With Orexo AB (publ)'s (STO:ORX) CEO Compensation And Here's Why
Key Insights Orexo to hold its Annual General Meeting on 8th of May CEO Nikolaj Sorensen's total compensation includes...
New Narrative • Apr 10
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Legal settlements and strategic changes stabilize revenue streams, enhancing future planning and financial clarity for Orexo.Analysis Article • Dec 20
A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Orexo AB (publ) ( STO:ORX ) shareholders would be excited to see that the share price has had a great month, posting a...Analysis Article • Nov 05
Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Orexo AB (publ) ( STO:ORX ) share price has fared very poorly over the last month, falling by a substantial 26...Analysis Article • Aug 02
Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Orexo AB (publ) ( STO:ORX ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Jul 20
Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
The analyst might have been a bit too bullish on Orexo AB (publ) ( STO:ORX ), given that the company fell short of...Analysis Article • May 29
Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Orexo AB (publ) ( STO:ORX ) shares have been powering on, with a gain of 28% in the last...Analysis Article • Apr 03
Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Orexo AB (publ)'s ( STO:ORX ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...Analysis Article • Dec 09
We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -SEK 423m |
| Mar 31 2026 | n/a | n/a | -SEK 418m |
| Dec 31 2025 | SEK 7m | SEK 4m | -SEK 403m |
| Sep 30 2025 | n/a | n/a | -SEK 609m |
| Jun 30 2025 | n/a | n/a | -SEK 621m |
| Mar 31 2025 | n/a | n/a | -SEK 560m |
| Dec 31 2024 | SEK 7m | SEK 4m | -SEK 478m |
| Sep 30 2024 | n/a | n/a | -SEK 105m |
| Jun 30 2024 | n/a | n/a | -SEK 97m |
| Mar 31 2024 | n/a | n/a | -SEK 73m |
| Dec 31 2023 | SEK 6m | SEK 4m | -SEK 128m |
| Sep 30 2023 | n/a | n/a | -SEK 201m |
| Jun 30 2023 | n/a | n/a | -SEK 195m |
| Mar 31 2023 | n/a | n/a | -SEK 218m |
| Dec 31 2022 | SEK 6m | SEK 4m | -SEK 178m |
| Sep 30 2022 | n/a | n/a | -SEK 152m |
| Jun 30 2022 | n/a | n/a | -SEK 177m |
| Mar 31 2022 | n/a | n/a | -SEK 216m |
| Dec 31 2021 | SEK 10m | SEK 4m | -SEK 223m |
| Sep 30 2021 | n/a | n/a | -SEK 207m |
| Jun 30 2021 | n/a | n/a | -SEK 240m |
| Mar 31 2021 | n/a | n/a | -SEK 198m |
| Dec 31 2020 | SEK 9m | SEK 3m | -SEK 84m |
| Sep 30 2020 | n/a | n/a | SEK 4m |
| Jun 30 2020 | n/a | n/a | SEK 201m |
| Mar 31 2020 | n/a | n/a | SEK 288m |
| Dec 31 2019 | SEK 6m | SEK 3m | SEK 219m |
Compensation vs Market: Nikolaj's total compensation ($USD734.29K) is above average for companies of similar size in the Swedish market ($USD398.72K).
Compensation vs Earnings: Nikolaj's compensation has been consistent with company performance over the past year.
CEO
Nikolaj Sorensen (54 yo)
13.5yrs
Tenure
SEK 6,993,000
Compensation
Mr. Nikolaj Sørensen serves as Independent Director at Bioservo Technologies AB (publ) since May 6, 2019. He was Director at Gesynta Pharma AB until 2025. Mr. Sorensen was Independent Director of Moberg Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 13.5yrs | SEK 6.99m | 0.62% SEK 3.2m | |
| Executive VP & CFO | 4yrs | no data | 0.12% SEK 611.9k | |
| Senior VP & Head of Operations | 7.6yrs | no data | 0.068% SEK 351.4k | |
| Investor Relations & Communications Director | no data | no data | no data | |
| Senior VP and Head of R&D | 7.6yrs | no data | 0.088% SEK 450.4k | |
| Senior VP & Chief Medical Officer | 3.8yrs | no data | no data | |
| Senior Vice President of Products & Portfolio Strategy | less than a year | no data | no data | |
| Senior Vice President of Business Development | less than a year | no data | no data |
4.0yrs
Average Tenure
52yo
Average Age
Experienced Management: ORX's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 7.3yrs | SEK 400.00k | 0.040% SEK 205.8k | |
| Independent Chairman | 1.7yrs | SEK 1.15m | 0.054% SEK 279.3k | |
| Independent Director | 4.3yrs | SEK 650.00k | 0.032% SEK 165.2k | |
| Director | 2.8yrs | SEK 400.00k | 0.022% SEK 113.4k |
3.6yrs
Average Tenure
63yo
Average Age
Experienced Board: ORX's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 11:37 |
| End of Day Share Price | 2026/08/04 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orexo AB (publ) is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |